Ionis Pharmaceuticals, Inc.
IONS
$32.96
$0.060.18%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 226.58M | 133.81M | 225.25M | 119.50M | 324.51M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 226.58M | 133.81M | 225.25M | 119.50M | 324.51M |
Cost of Revenue | 249.32M | 220.83M | 226.23M | 216.37M | 259.62M |
Gross Profit | -22.74M | -87.02M | -978.00K | -96.87M | 64.89M |
SG&A Expenses | 88.08M | 61.64M | 65.11M | 52.64M | 51.01M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 337.40M | 282.47M | 291.34M | 269.01M | 310.63M |
Operating Income | -110.82M | -148.66M | -66.09M | -149.51M | 13.88M |
Income Before Tax | -107.04M | -144.10M | -66.20M | -142.73M | -2.77M |
Income Tax Expenses | -2.69M | -3.62M | 64.00K | 75.00K | 6.50M |
Earnings from Continuing Operations | -104.35M | -140.48M | -66.27M | -142.80M | -9.26M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -104.35M | -140.48M | -66.27M | -142.80M | -9.26M |
EBIT | -110.82M | -148.66M | -66.09M | -149.51M | 13.88M |
EBITDA | -108.12M | -145.68M | -63.00M | -146.33M | 17.08M |
EPS Basic | -0.66 | -0.95 | -0.45 | -0.98 | -0.06 |
Normalized Basic EPS | -0.41 | -0.61 | -0.27 | -0.62 | 0.08 |
EPS Diluted | -0.66 | -0.95 | -0.45 | -0.98 | -0.06 |
Normalized Diluted EPS | -0.41 | -0.61 | -0.27 | -0.62 | 0.08 |
Average Basic Shares Outstanding | 158.00M | 148.59M | 145.96M | 145.54M | 144.00M |
Average Diluted Shares Outstanding | 158.00M | 148.59M | 145.96M | 145.54M | 144.00M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |